<DOC>
	<DOCNO>NCT02454283</DOCNO>
	<brief_summary>LGN-VN-003 prospective , multi-center , randomize , double-blind , placebo-controlled study evaluate safety efficacy single oral dose vanoxerine conversion subject recent onset atrial fibrillation ( AF ) atrial flutter ( AFL ) normal sinus rhythm . Up 625 subject randomize 2:1 fashion least 400 vanoxerine 200 placebo subject receive study drug .</brief_summary>
	<brief_title>Safety Efficacy Vanoxerine Conversion Subjects With Recent Onset Atrial Fibrillation Flutter Normal Sinus Rhythm</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vanoxerine</mesh_term>
	<criteria>Subject inform investigational nature study give write informed consent accordance institutional , local , national guideline . Able return Day 8 follow . Male female 18 year age great . Onset AF/AFL within 7 calendar day precede randomization , base symptom . AF/AFL document ECG screen period . Adherence local clinical standard ACC/AHA ESC practice guideline AF/AFL regard thromboembolic event prevention treatment . Previous exposure vanoxerine HCl . Women childbearing potential ( neither surgically sterilize postmenopausal define cessation menses one year ) Systolic blood pressure &lt; 110 mmHg ( unless document usual value ) . Average heart rate &lt; 60 bpm document screen ECG . Average QTc &gt; 440 msec document screen ECG . QRS interval &gt; 140 msec document screen ECG . Paced atrial rhythm screen ECG . History receive another Class I Class III antiarrhythmic drug within 3 day prior randomization . Excluded Class I antiarrhythmic drug include quinidine , procainamide , disopyramide , lignocaine , mexilitine , flecainide , propafenone . Excluded Class III drug include dofetilide , sotalol , dronedarone , ranolazine . History amiodarone ( oral IV ) within 90 day prior randomization . Native prosthetic aortic mitral stenosis aortic valve area â‰¤1.0 cm2 mitral valve area &lt; 1.5 cm2 valvular disease surgery indicate . Treatment loop diuretic ( e.g. , furosemide , bumetanide , torsemide , ethacrynic acid , etc . ) 30 day prior randomization . Ejection fraction &lt; 35 % within 3 month prior randomization ( recent measure one ) . AF/AFL result surgery ( postoperative AF/AFL ) within 30 day prior randomization . History electrical cardioversion within 7 calendar day prior randomization . History polymorphic ventricular tachycardia include torsades de pointes . History family history long QT syndrome inherit arrhythmia syndrome . History ventricular tachycardia require drug device therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>